Details for Patent: 9,187,405

Which drugs does patent 9,187,405 protect, and when does it expire?

Patent 9,187,405 protects GILENYA and is included in one NDA.

Protection for GILENYA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-six patent family members in twenty countries.

Summary for Patent: 9,187,405

Title:	S1P receptor modulators for treating relasping-remitting multiple sclerosis
Abstract:	The present invention relates uses of an S1P receptor modulator such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e. g. a compound comprising a group of formula X ##STR00001## for the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis.
Inventor(s):	Hiestand; Peter C. (Austria, CH), Schnell; Christian (Hesingue, FR)
Assignee:	Novartis AG (Basel, CH)
Application Number:	14/257,342
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,187,405
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,187,405

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-001	Sep 21, 2010	AB	RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 9,187,405

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0612721.1	Jun 27, 2006

International Family Members for US Patent 9,187,405

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007264031
Australia	2011201844
Australia	2013200356